Luis Filipe Costa-Machado

Luis Filipe Costa-Machado

Auto-generated profile, based on publicly available information

Luis Filipe Costa-Machado

Metabolic Syndrome Group – BIOPROMET. Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM + CSIC, Madrid, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in Cell Cycle
Verified
Journal Article
Closed access
LCLuis Filipe Costa-Machado
Luis Filipe Costa-Machado
DFDr. Pablo José Fernandez-Marcos
Dr. Pablo José Fernandez-Marcos
Sirtuins are a family of protein deacylases and ADP-ribosyl-transferases, homologs to the yeast SIR2 protein. Seven sirtuin paralogs have been described in mammals, with different subcellular locations, targets, enzymatic activities, and regulatory mechanisms. All sirtuins share NAD+ as substrate, placing them as central metabolic hubs with strong relevance in lifespan, metabolism, and cancer development. Much effort has been devoted to studying the roles of sirtuins in cancer, providing a wealth of data on sirtuins roles in mouse models and humans. Also, extensive data are available on the effects of pharmacological modulation of sirtuins in cancer development. Here, we present a comprehensive and organized resume of all the existing evidence linking every sirtuin with cancer development. From our analysis, we conclude that sirtuin modulation after tumor initiation results in unpredictable outcomes in most tumor types. On the contrary, all genetic and pharmacological models indicate that sirtuins activation prior to tumor initiation can constitute a powerful preventive strategy.

15 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLuis Filipe Costa-Machado
Luis Filipe Costa-Machado
EGEsther García-Domínguez
Esther García-Domínguez
RMRebecca L. McIntyre
Rebecca L. McIntyre
JLJose Luis Lopez-Aceituno
Jose Luis Lopez-Aceituno
ÁBÁlvaro Ballesteros-Gonzalez
Álvaro Ballesteros-Gonzalez
DFDr. Pablo José Fernandez-Marcos
Dr. Pablo José Fernandez-Marcos
Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood–brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis.

18 July 2018 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
LCLuis Filipe Costa‐Machado
Luis Filipe Costa‐Machado
RMRoberto Martín-Hernández
Roberto Martín-Hernández
MSMiguel Ángel Sanchez‐Luengo
Miguel Ángel Sanchez‐Luengo
KHKatharina Hess
Katharina Hess
CVClaudia Vales-Villamarín
Claudia Vales-Villamarín
DFDr. Pablo José Fernandez-Marcos
Dr. Pablo José Fernandez-Marcos